These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 23414465)
1. Urological medical oncology: land of opportunity. Jones R Future Oncol; 2013 Feb; 9(2):149-52. PubMed ID: 23414465 [TBL] [Abstract][Full Text] [Related]
2. Interview with Johann de Bono for Future Oncology. Interviewed by Francesca Lake. de Bono J Future Oncol; 2012 Nov; 8(11):1381-2. PubMed ID: 23148611 [TBL] [Abstract][Full Text] [Related]
3. Pazopanib for the treatment of renal cancer. Al-Marrawi MY; Rini B Expert Opin Pharmacother; 2011 May; 12(7):1171-89. PubMed ID: 21470066 [TBL] [Abstract][Full Text] [Related]
4. Olaparib recommendations for ovarian cancer patients. Johnson P; Westcott G Future Oncol; 2016 Jan; 12(2):149-51. PubMed ID: 26616222 [TBL] [Abstract][Full Text] [Related]
5. Nursing considerations with pazopanib therapy: focus on metastatic renal cell carcinoma. Bourdeanu L; Twardowski P; Pal SK Clin J Oncol Nurs; 2011 Oct; 15(5):513-7. PubMed ID: 21951737 [TBL] [Abstract][Full Text] [Related]
6. Trials and tribulations of cytotoxic and targeted breast cancer therapy: a clinical perspective on the next phase of progress. Interview by Sophia Maprayil and Alexandra Hemsley. Twelves C Expert Rev Anticancer Ther; 2013 Mar; 13(3):251-5. PubMed ID: 23477510 [TBL] [Abstract][Full Text] [Related]
7. Pazopanib for the treatment of metastatic renal cell carcinoma. Pick AM; Nystrom KK Clin Ther; 2012 Mar; 34(3):511-20. PubMed ID: 22341567 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of pazopanib in the treatment of renal cell carcinoma. Zivi A; Cerbone L; Recine F; Sternberg CN Expert Opin Drug Saf; 2012 Sep; 11(5):851-9. PubMed ID: 22861374 [TBL] [Abstract][Full Text] [Related]
9. The history and future of the Urologic Oncology Study Group (UOSG) of the Japan Clinical Oncology Group (JCOG). Tobisu K Jpn J Clin Oncol; 2012 May; 42(5):363-7. PubMed ID: 22450928 [TBL] [Abstract][Full Text] [Related]
14. Pazopanib. Kidney cancer: many risks, but is there a benefit for patients? Prescrire Int; 2011 Mar; 20(114):64-6. PubMed ID: 21648224 [TBL] [Abstract][Full Text] [Related]
15. Photodynamic therapy in urology: what can we do now and where are we heading? Bozzini G; Colin P; Betrouni N; Nevoux P; Ouzzane A; Puech P; Villers A; Mordon S Photodiagnosis Photodyn Ther; 2012 Sep; 9(3):261-73. PubMed ID: 22959806 [TBL] [Abstract][Full Text] [Related]
16. [Active studies of the Working Association for Urological Oncology (AUO) in 2006]. Rexer H Urologe A; 2006 Feb; 45(2):229-40. PubMed ID: 16440204 [No Abstract] [Full Text] [Related]
18. Changes and challenges: a career in prostate surgery. Kirby R Future Oncol; 2013 Sep; 9(9):1267-9. PubMed ID: 23980673 [TBL] [Abstract][Full Text] [Related]
19. Pazopanib, a new therapy for metastatic soft tissue sarcoma. Verweij J; Sleijfer S Expert Opin Pharmacother; 2013 May; 14(7):929-35. PubMed ID: 23488774 [TBL] [Abstract][Full Text] [Related]
20. Nursing considerations for patients receiving pazopanib for renal cell carcinoma. Becze E ONS Connect; 2012 Feb; 27(2):16-7. PubMed ID: 22375508 [No Abstract] [Full Text] [Related] [Next] [New Search]